{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:17:13Z","timestamp":1788797833710,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hellenic Journal of Cardiology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.hjc.2022.12.002","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T20:44:33Z","timestamp":1670273073000},"page":"26-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis"],"prefix":"10.1016","volume":"71","author":[{"given":"Athanasios","family":"Manolis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8256-4218","authenticated-orcid":false,"given":"Manolis","family":"Kallistratos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9525-0971","authenticated-orcid":false,"given":"Leonidas","family":"Poulimenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Zamfir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-6029","authenticated-orcid":false,"given":"Costas","family":"Thomopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hjc.2022.12.002_bib1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ijcard.2016.06.150","article-title":"Medical treatment of stable angina: A tailored therapeutic approach","volume":"220","author":"Manolis","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hjc.2022.12.002_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejim.2019.09.013","article-title":"Impact of stable angina on health status and quality of life perception of currently treated patients. The BRIDGE 2 survey","volume":"70","author":"Manolis","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.hjc.2022.12.002_bib3","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.hjc.2022.12.002_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejim.2019.12.012","article-title":"The ESC 2019 CCS guidelines: Have we left our patients and scientific evidence behind?","volume":"72","author":"Manolis","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.hjc.2022.12.002_bib5","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hjc.2022.12.002_bib6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hjc.2022.12.002_bib7","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.105.597500","article-title":"Ranolazine for the Treatment of Chronic Angina and Potential Use in Other Cardiovascular Conditions","volume":"113","author":"Chaitman","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hjc.2022.12.002_bib8","first-page":"CD011747","article-title":"Ranolazine for stable angina pectoris","volume":"2","author":"Salazar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.hjc.2022.12.002_bib9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijcard.2013.08.131","article-title":"Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis","volume":"169","author":"Savarese","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hjc.2022.12.002_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.hrthm.2016.10.008","article-title":"Role of ranolazine in the prevention and treatment of atrial fibrillation: A meta-analysis of randomized clinical trials","volume":"14","author":"Gong","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hjc.2022.12.002_bib11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijcard.2016.11.103","article-title":"Ranolazine for rhythm control in atrial fibrillation: A systematic review and meta-analysis","volume":"227","author":"Guerra","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hjc.2022.12.002_bib12","article-title":"Ranolazine a contemporary review","volume":"5","author":"Rayner-Hartley","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.hjc.2022.12.002_bib13","article-title":"Efficacy and safety of ranolazine in diabetic patients: A systematic review and meta-analysis","author":"Zeng","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.hjc.2022.12.002_bib14","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.hjc.2022.12.002_bib15","doi-asserted-by":"crossref","first-page":"I4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.hjc.2022.12.002_bib16","series-title":"Cochrane handbook for systematic reviews of interventions","article-title":"Chapter 7: selecting studies and collecting data","author":"Higgins","year":"2011"},{"key":"10.1016\/j.hjc.2022.12.002_bib17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1161\/01.CIR.90.2.726","article-title":"Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group","volume":"90","author":"Thadani","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.hjc.2022.12.002_bib18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0002-9149(99)00190-3","article-title":"A\u00a0controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group","volume":"84","author":"Pepine","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hjc.2022.12.002_bib19","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hjc.2022.12.002_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.hjc.2022.12.002_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.amjcard.2004.09.025","article-title":"Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris","volume":"95","author":"Rousseau","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hjc.2022.12.002_bib22","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina)","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hjc.2022.12.002_bib23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial","volume":"48","author":"Stone","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hjc.2022.12.002_bib24","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.hjc.2022.12.002_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0140-6736(15)00459-6","article-title":"RIVER-PCI investigators. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Weisz","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hjc.2022.12.002_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1074248418784290","article-title":"Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial","volume":"24","author":"Schwemer","year":"2019","journal-title":"J\u00a0Cardiovasc Pharmacol Therapeut"},{"key":"10.1016\/j.hjc.2022.12.002_bib27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.amjcard.2019.05.063","article-title":"Effects of exercise training with and without ranolazine on peak oxygen consumption, daily physical activity, and quality of life in patients with chronic stable angina pectoris","volume":"124","author":"Willis","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hjc.2022.12.002_bib28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/TCRM.S82288","article-title":"Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: randomized, double-blind crossover pilot study","volume":"11","author":"Shammas","year":"2015","journal-title":"Therapeut Clin Risk Manag"},{"key":"10.1016\/j.hjc.2022.12.002_bib29","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/eurheartj\/ehv647","article-title":"A\u00a0randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve","volume":"37","author":"Bairey Merz","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hjc.2022.12.002_bib30","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/echo.12674","article-title":"Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease","volume":"32","author":"Tagliamonte","year":"2015","journal-title":"Echocardiography"},{"key":"10.1016\/j.hjc.2022.12.002_bib31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjcard.2013.02.045","article-title":"Effects of ivabradine and ranolazine in patients with microvascular angina pectoris","volume":"112","author":"Villano","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hjc.2022.12.002_bib32","first-page":"8","article-title":"Ranolazine reduces symptoms of palpitations and documented arrhythmias in patients with ischemic heart disease \u2014 The RYPPLE randomized cross-over trial","volume":"7","author":"Pelliccia","year":"2015","journal-title":"IJC Metabolic & Endocrine"},{"key":"10.1016\/j.hjc.2022.12.002_bib33","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.ahj.2012.03.018","article-title":"A\u00a0pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention","volume":"163","author":"Pelliccia","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.hjc.2022.12.002_bib34","article-title":"Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function","volume":"6","author":"Shah","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"Suppl C","key":"10.1016\/j.hjc.2022.12.002_bib35","article-title":"Angina and hypertension","volume":"21","author":"Manolis","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.hjc.2022.12.002_bib36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000362381","article-title":"The J-curve in arterial hypertension: fact or fallacy?","volume":"129","author":"Tsika","year":"2014","journal-title":"Cardiology"},{"key":"10.1016\/j.hjc.2022.12.002_bib37","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/00004872-200018110-00023","article-title":"Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy","volume":"18","author":"Ambrosioni","year":"2000","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.hjc.2022.12.002_bib38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nrcardio.2017.131","article-title":"Expert consensus document: A 'diamond' approach to personalized treatment of angina","volume":"15","author":"Ferrari","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.hjc.2022.12.002_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejim.2021.08.003","article-title":"State of the art approach to managing angina and ischemia: tailoring treatment to the evidence","volume":"92","author":"Manolis","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.hjc.2022.12.002_bib40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jacc.2006.09.045","article-title":"Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization","volume":"49","author":"Berry","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hjc.2022.12.002_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2017-000706","article-title":"Effect of ranolazine on glycaemia in adults with and without diabetes: a meta-analysis of randomised controlled trials","volume":"5","author":"Teoh","year":"2018","journal-title":"Open Heart"},{"key":"10.1016\/j.hjc.2022.12.002_bib42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/jpet.110.176396","article-title":"Ranolazine increases b-cell survival and improves glucose homeostasis in low-dose streptozotocininduced diabetes in mice","volume":"337","author":"Ning","year":"2011","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.hjc.2022.12.002_bib43","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.2337\/db13-1562","article-title":"Blockade of Na+ channels in pancreatic \u03b1-cells has antidiabetic effects","volume":"63","author":"Dhalla","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.hjc.2022.12.002_bib44","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","article-title":"Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: A scientific statement from the American Heart Association","volume":"141","author":"Arnold","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.hjc.2022.12.002_bib45","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/eurheartj\/ehu467","article-title":"Wilder's principle: pre-treatment value determines post-treatment response","volume":"36","author":"Messerli","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hjc.2022.12.002_bib46","first-page":"124","article-title":"Impact of ranolazine on ventricular arrhythmias - A systematic review","volume":"34","author":"Bazoukis","year":"2018","journal-title":"J\u00a0Arrhythm"}],"container-title":["Hellenic Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966622001762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966622001762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:15:02Z","timestamp":1761099302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1109966622001762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":46,"alternative-id":["S1109966622001762"],"URL":"https:\/\/doi.org\/10.1016\/j.hjc.2022.12.002","relation":{},"ISSN":["1109-9666"],"issn-type":[{"value":"1109-9666","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Hellenic Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hjc.2022.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Hellenic Society of Cardiology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}